Union Minister inaugurates Special Handloom Expo (See 'Corp Brief') India, Brazil sign TKDL Access Agreement for protection of Patent (See 'Corp Brief') Memorandum of Cooperation signed between Digital Bharat Nidhi and AP (See 'Corp Brief') IPR - Registered mark is liable to be removed if not used for continuous period of five years & three months prior to filing of petition, unless special circumstances are shown: HC (See 'Legal Desk') Footwear Design and Development Institute celebrates 5th Convocation Ceremony (See 'Corp Brief') 96% houses under PMAY-U 2.0 allotted for women (See 'Corp Brief') SEBI - Adjudication proceedings are nullified where the noticee has ceased to exist on account of being struck off the RoC: SEBI (See 'Legal Desk') India-Brazil MoU signed to Deepen MSME Cooperation (See 'Corp Brief') IFSCA-IICA unveil Strategic Roadmap to institutionalize Corporate Governance Ecosystem at GIFT-IFSC (See 'Corp Brief') Grant support extended to 5 Innovators under CSR-backed Programme (See 'Corp Brief') Misc - Notice u/s 91 of CrPC cannot be issued to accused person to compel them to furnish information that is based on their personal knowledge: HC (See 'Legal Desk') MoS holds bilateral Talks with Rwanda ICT Minister (See 'Corp Brief') India, Brazil sign MoU to strengthen and secure steel supply chain (See 'Corp Brief') Misc - SICA - failure to repay dues or subsequent financial incapacity cannot constitute cheating in he absence of fraudulent intent at time of inducement: HC (See 'Legal Desk') Supreme Court Clears Path For Single Insolvency Proceedings Against Linked Group Companies (See CORP EINSICHT)

Print

CCI olays 20% equity buy of Piramal Pharma by Clover Investments

Published: Sep 12, 2020

By TIOLCORPLAWS News Service

NEW DELHI, SEPT 12, 2020: The Competition Commission of India (CCI) approves proposed combination involving acquisition of 20% of the issued and paid-up equity share capital of Piramal Pharma Limited (Pharma Co.) by CA Clover Intermediate II Investments (Curie).

The proposed combination relates to (i) the transfer of global pharmaceutical business ( Transferred Business ) by Piramal Enterprises Limited ( PEL ) to a wholly owned subsidiary of PEL, i.e. Pharma Co., followed by, (ii) the acquisition of 20% of the issued and paid-up equity share capital of Pharma Co. by Curie ( Proposed Combination ).

Curie is a special purpose acquisition vehicle, owned and controlled by investment funds advised by the affiliates of the Carlyle Group Inc. (“ Carlyle Group ”).

The Carlyle Group is a global alternative asset manager, which manages funds that invest globally across four investment disciplines: (i) Corporate Private Equity (buyout and growth capital), (ii) Real Assets (real estate, infrastructure and energy and renewable resources), (iii) Global Credit (leveraged loans and structured credit, opportunistic credit, energy credit, private credit and distressed credit), and (iv) Solutions (private equity fund of funds program and related co-investment and secondary activities).

Pharma Co. is a wholly owned entity of PEL that will hold PEL's Transferred Business as part of the Proposed Combination, and acquire the pharmaceutical business of PEL comprising the Contract Development and Manufacturing Organisation ( CDMO ), Complex Hospital Generics ( CHG ), and Consumer Healthcare Division ( CHD )segments, as well as equity interest in certain PEL entities.

TIOL CORP SEARCH

TIOL GROUP WEBSITES

taxindiaonline
taxindiainternational
tioltube
TKF
TIOLawards
A TIOL Website. Copyright © 2025 TIOLcorplaws.com All rights reserved.